Dermatology Advisor

DermatologyAdvisor.com serves as a valuable resource for dermatologists and healthcare professionals, delivering a wealth of practical information and tools to help them make informed decisions for their patients. The goal of Dermatology Advisor is to equip dermatologists and healthcare providers who treat skin and related conditions with up-to-date, relevant educational content that enhances their clinical practice and elevates patient care. The platform also offers practice management tools and continuing education programs, creating a comprehensive digital experience that tackles many challenges faced by dermatology professionals today.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#399260

United States

#185925

Health/Medicine

#1446

Traffic sources

Monthly visitors

Articles

Adolescents Experience Greater QOL Effects Due to Alopecia Areata Than Adults

4 days ago | dermatologyadvisor.com | Ron Goldberg

Adults and adolescents with alopecia areata who have 50% or greater scalp hair loss (SHL) experience a significant effect on quality of life (QOL), with a greater effect on QOL seen among adolescents than adults. These study findings were published in Dermatology and Therapy. Investigators evaluated QOL in adults and adolescents to gage the effect of age at the time of experiencing significant SHL due to alopecia.
FDA Approves Ustekinumab Biosimilar Starjemza

5 days ago | dermatologyadvisor.com | Jaymin Kang

The Food and Drug Administration (FDA) has approved Starjemza® (ustekinumab-hmny), a biosimilar to Stelara® (ustekinumab), for the treatment of various chronic inflammatory diseases.
Uveitis Is Bidirectionally Associated With Psoriatic Disease

1 week ago | dermatologyadvisor.com | Ron Goldberg

Psoriatic diseases are associated with an increased risk for uveitis, with this positive association more likely to occur in patients with psoriatic arthritis than those with psoriasis without arthritis, according to the results of a meta-analysis published in the Journal of Cutaneous Medicine and Surgery. Investigators sought to clarify the bidirectional association between psoriatic diseases and uveitis.
Zevtera Availability Provides New Option for Serious Bacterial Infections

1 week ago | dermatologyadvisor.com | Jaymin Kang

Zevtera® (ceftobiprole medocaril sodium for injection) is now available for the treatment of: adults with Staphylococcus aureus bloodstream infections (bacteremia; SAB), including those with right-sided infective endocarditis; adults with acute bacterial skin and skin structure infections (ABSSSI); and adult and pediatric patients 3 months to less than 18 years of age with community-acquired bacterial pneumonia (CABP).
Zoryve Foam 0.3% Approved for Plaque Psoriasis of the Scalp, Body

1 week ago | dermatologyadvisor.com | Diana Ernst

The Food and Drug Administration (FDA) has approved Zoryve® (roflumilast) topical foam, 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients aged 12 years and older. Zoryve foam contains roflumilast, a phosphodiesterase type 4 inhibitor. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and body.
Features Distinguish Hand Eczema From Hand Psoriasis Without Invasive Testing

1 week ago | dermatologyadvisor.com | Lisa M Kuhns

Clinical features, morphology, and patient demographics can effectively distinguish hand eczema from hand psoriasis, according to study results published in Dermatitis. Researchers conducted a retrospective chart review at a single tertiary-care hospital in Thailand from January 2015 to November 2022 to identify distinguishing clinical characteristics to differentiate hand eczema from hand psoriasis without the need for invasive diagnostic procedures.
Adalimumab Biosimilar Yuflyma Now Fully Interchangeable

1 week ago | dermatologyadvisor.com | Diana Ernst

The Food and Drug Administration (FDA) has expanded the interchangeable designation for Yuflyma® (adalimumab-aaty), a biosimilar to Humira® (adalimumab), to include all presentations of the product. Yuflyma, a tumor necrosis factor (TNF) blocker, was approved in May 2023 as a citrate-free, high-concentration biosimilar to Humira.
Rilzabrutinib May Improve Antihistamine-Refractory Chronic Spontaneous Urticaria

1 week ago | dermatologyadvisor.com | Colby Stong

Rilzabrutinib may be effective for patients with H1-antihistamine–refractory chronic spontaneous urticaria (CSU), according to the results of a study published in JAMA Dermatology.
Large Flap Reconstruction Under Local Anesthesia Is Safe in Outpatient Settings

1 week ago | dermatologyadvisor.com | Ron Goldberg

Large flap reconstructions under local anesthesia in the outpatient setting are safe with a low overall complication rate, according to study findings published in Dermatologic Surgery. Investigators evaluated the postoperative incidence of complications following outpatient dermatologic reconstruction using large adjacent tissue transfer of flap areas 60 cm2 or greater under local anesthesia to establish the safety of these procedures.
Anti-OX40 Medications May Be Promising Novel Therapies for Atopic Dermatitis

1 week ago | dermatologyadvisor.com | Jessica Nye

A systematic review and meta-analysis published in Dermatitis found that anti-OX40 therapies are effective at treating moderate to severe atopic dermatitis (AD) and have an acceptable safety profile. Anti-OX40 therapies are a group of novel therapeutics that target the OX40 pathway, which is a costimulatory receptor on activated T cells that are involved in inflammatory responses and the maintenance of immune memory.